Website
News25/Ratings6
News · 26 weeks15-83%
2025-10-262026-04-19
Mix890d
- SEC Filings4(50%)
- Other2(25%)
- Insider1(13%)
- Earnings1(13%)
Latest news
25 items- PRPaysign to Host First Quarter 2026 Earnings CallPaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss first quarter 2026 earnings at 5:00 p.m. Eastern time on Tuesday, May 12, 2026. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13760115 The replay will be available until August 12, 2026. To register as a financial professional in order to ask questions during the call, please email ir@paysign.com no later than 5:00 p.m.
- SECSEC Form DEFA14A filed by Paysign Inc.DEFA14A - Paysign, Inc. (0001496443) (Filer)
- SECSEC Form DEF 14A filed by Paysign Inc.DEF 14A - Paysign, Inc. (0001496443) (Filer)
- SECSEC Form 10-K filed by Paysign Inc.10-K - Paysign, Inc. (0001496443) (Filer)
- SECPaysign Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Paysign, Inc. (0001496443) (Filer)
- PRPaysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin ExpansionMix Shift Drives Gross and Operating Margin Expansion Strong Balance Sheet Enables Continued Investment for Profitable Growth Paysign, Inc. (NASDAQ:PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the fourth quarter and full-year 2025. Full-Year Financial Highlights Full-year 2025 total revenues of $82.0 million, up 40.5% from 2024 Total net plasma center count increased by 115 during 2025, exiting the year with 595 centers, contributing to a 4.0% increase in plasma revenue versus the same period
- INSIDERChief Financial Officer Baker Jeffery Bradford covered exercise/tax liability with 26,055 shares and converted options into 60,000 shares, increasing direct ownership by 10% to 386,218 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- PRPaysign to Host Fourth Quarter and Full Year 2025 Earnings CallPaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss fourth quarter and full year 2025 earnings at 5:00 p.m. Eastern time on Tuesday, March 24, 2026. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13758162 The replay will be available until June 24, 2026. To register as a financial professional in order to ask questions during the call, please email ir@paysign.com no later
- PRPaysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth ConferencePaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced it will be presenting at the Oppenheimer 11th Annual Emerging Growth Conference to be held February 3-4, 2026, through a virtual format. The focus of the virtual conference is to feature one-on-one and small group meetings with emerging companies in technology, industrial growth and consumer sectors. Paysign's Chief Financial Officer, Jeff Baker, will host one-on-one meetings on Tuesday, February 3. Investors interested in registering may contact their Oppe
- PRPaysign, Inc. Announces 2025 Performance Analysis of Patient Affordability SolutionsDynamic Business Rules Demonstrates the Company's Advanced Capabilities in Mitigating Copay Maximizers, Exiting 2025 With 131 Active Programs Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions and integrated payment processing for the life sciences industries, today announced its annual performance analysis of pharmaceutical copay programs. The company added 55 programs during 2025, exiting the year with 131 programs – many incorporating Paysign's Dynamic Business Rules feature, which saved pharmaceutical clients more than $325 million by mitigating the harmful financial impact of copay maximizers on patients and program sponso
- INSIDERChief Legal Officer Strobo Robert sold $109,400 worth of shares (20,000 units at $5.47), decreasing direct ownership by 6% to 327,290 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- PRPaysign, Inc. to Present at the 17th Annual Southwest IDEAS Investor ConferencePaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced they will be presenting at the 17th Annual Southwest IDEAS Investor Conference to be held Wednesday and Thursday, November 19 and 20, 2025, in Dallas, Texas. The conference is an annual invitation-only event, featuring quality public companies to interact with top institutional investors. The format has been designed to give attendees direct access to senior management via one-on-one and group meeting formats. Paysign's Chief Financial Officer, Jeff Baker,
- SECSEC Form 10-Q filed by Paysign Inc.10-Q - Paysign, Inc. (0001496443) (Filer)
- SECPaysign Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Paysign, Inc. (0001496443) (Filer)
- PRPaysign, Inc. Reports Third Quarter 2025 Financial ResultsDelivered strong performance with record revenue and improved profitability Third quarter 2025 total revenues of $21.60 million, up 41.6% from third quarter 2024 Third quarter 2025 net income of $2.22 million, up 54.2% from $1.44 million a year ago, while diluted earnings per share was $0.04 versus $0.03 for third quarter 2024 Third quarter 2025 Adjusted EBITDA of $5.04 million (23.3% of revenues), up 78.1% from $2.83 million (18.5% of revenues) a year ago, while diluted Adjusted EBITDA per share was $0.08 versus $0.05 for third quarter 20241 Year-over-year plasma revenue increased 12.4% to $12.86 million; exited the quarter with 595 plasma centers, an increase of 117 plasma ce
- PRPaysign to Host Third Quarter 2025 Earnings CallPaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management software platforms and integrated payment processing for the life sciences industries, will discuss third quarter 2025 earnings at 5:00 p.m. Eastern time on Wednesday, November 12, 2025. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13756404 The replay will be available until May 12, 2026. To register as a financial professional in order to ask questions during the call, please email ir@paysign.com no later th
- INSIDERChief Legal Officer Strobo Robert was granted 100,000 shares, increasing direct ownership by 40% to 347,290 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- INSIDERCEO Newcomer Mark was granted 200,000 shares, increasing direct ownership by 2% to 8,950,728 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- INSIDERChief Payments Officer Lanford Matthew Louis was granted 33,334 shares, increasing direct ownership by 23% to 180,698 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- INSIDEREVP, Operations Herman Joan M was granted 16,667 shares, increasing direct ownership by 2% to 838,250 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- INSIDERChief Financial Officer Baker Jeffery Bradford was granted 100,000 shares, increasing direct ownership by 40% to 352,273 units (SEC Form 4)4 - Paysign, Inc. (0001496443) (Issuer)
- PRPaysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science SolutionsGarcia Tapped to Lead Strategy for Company's Life Science Solutions Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management software platforms and integrated payment processing for the life sciences industries, today announced that it has appointed Jose Garcia as Executive Vice President, Life Science Solutions. In his new role at Paysign, Mr. Garcia will implement and execute the market strategy for the company's comprehensive suite of engagement and management solutions targeting the life sciences industries. With more than two decades of executive experience in life sciences services, Mr. Garcia is a
- SECPaysign Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Paysign, Inc. (0001496443) (Filer)
- PRPaysign, Inc. Opens 30,000 Square Foot Patient Service Support Center to Meet Growing Demand in Patient Affordability BusinessPaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced the opening of a new 30,000 square foot patient service support center in Henderson, Nevada. The facility increases Paysign's support capacity fourfold and will bolster the company's rapidly growing patient affordability business. The expansion reflects Paysign's strategic focus on scaling operations to meet rapidly growing demand from pharmaceutical manufacturers seeking more effective patient affordability solutions. This demand is being driven by Paysign's
- PRPaysign, Inc. to Present at the Lake Street Best Ideas Growth BIG9 ConferencePaysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced they will be attending the ninth annual Lake Street Best Ideas Growth BIG9 Conference to be held Thursday, September 11, 2025. The conference is an annual invitation-only event, featuring dynamic, small-cap companies interacting with top institutional investors. The format has been designed to give attendees direct access to senior management via one-on-one and group meeting formats. Paysign's Chief Financial Officer, Jeff Baker, will be presenting to inves